Synthesis and some Pharmacological Properties of an Immunoactive Lysine-Containing Tetrapeptide
- Authors: Kholnazarov B.M.1, Bobizoda G.M.2, Olefir Y.V.1, Prokof’ev A.B.3,1, Sapovskii M.M.3, Evteev V.A.1, Bunyatyan N.D.3,1
-
Affiliations:
- Scientific Center for Expertise in Medicines, Russian Ministry of Health
- S. Aini Tajik State Pedagogical University
- I. M. Sechenov First Moscow State Medical Institute, Russian Ministry of Health (Sechenov University)
- Issue: Vol 52, No 7 (2018)
- Pages: 611-614
- Section: Article
- URL: https://journals.rcsi.science/0091-150X/article/view/245368
- DOI: https://doi.org/10.1007/s11094-018-1869-3
- ID: 245368
Cite item
Abstract
The potentially immunoactive lysine-containing tetrapeptide H-Lys-Ala-Val-Gly-OH was synthesized. The value of using a method based on mixed anhydrides and activated esters to obtain tetrapeptide at high yield was demonstrated. The peptide preparation method was improved by replacing p-nitrophenyl esters at the intermediate stage with N-hydroxysuccinimide esters, yielding a crystalline substance at high purity, and replacing the BOC (tert-butyloxycarbonyl) group for protection with a carbobenzoxy group, which provided for a one-step removal of the protection of both amino groups in mild conditions. Comparative assessment of the immunological activity of the tetrapeptide on the background of immunization with sheep erythrocytes in mice with other lysine-containing tetrapeptides showed it to have more marked immunostimulatory activity. Studies of acute and chronic toxicity demonstrated the absence of toxic activity in the lysine-containing tetrapeptide studied here on s.c. administration to experimental animals. The tetrapeptide corresponded to toxicity class 5, i.e., it was essentially nontoxic.
About the authors
B. M. Kholnazarov
Scientific Center for Expertise in Medicines, Russian Ministry of Health
Email: ndbun@mail.ru
Russian Federation, Moscow
G. M. Bobizoda
S. Aini Tajik State Pedagogical University
Email: ndbun@mail.ru
Tajikistan, Dushanbe
Yu. V. Olefir
Scientific Center for Expertise in Medicines, Russian Ministry of Health
Email: ndbun@mail.ru
Russian Federation, Moscow
A. B. Prokof’ev
I. M. Sechenov First Moscow State Medical Institute, Russian Ministry of Health (Sechenov University); Scientific Center for Expertise in Medicines, Russian Ministry of Health
Email: ndbun@mail.ru
Russian Federation, Moscow; Moscow
M. M. Sapovskii
I. M. Sechenov First Moscow State Medical Institute, Russian Ministry of Health (Sechenov University)
Email: ndbun@mail.ru
Russian Federation, Moscow
V. A. Evteev
Scientific Center for Expertise in Medicines, Russian Ministry of Health
Email: ndbun@mail.ru
Russian Federation, Moscow
N. D. Bunyatyan
I. M. Sechenov First Moscow State Medical Institute, Russian Ministry of Health (Sechenov University); Scientific Center for Expertise in Medicines, Russian Ministry of Health
Author for correspondence.
Email: ndbun@mail.ru
Russian Federation, Moscow; Moscow